EKSO (Ekso Bionics Holdings, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by EKSO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-20 | Jason C Jones | Chief Operating Officer | Buy | — | — |
| 2026-03-20 | Jerome Wong | Chief Financial Officer | Buy | — | — |
| 2026-02-20 | DANIEL ASHER | 10%+ Owner | Buy | — | — |
| 2026-02-19 | DANIEL ASHER | 10%+ Owner | Buy | — | — |
| 2026-02-17 | DANIEL ASHER | 10%+ Owner | Buy | — | — |
| 2026-01-07 | Jason C Jones | Chief Operating Officer | Sell | — | — |
| 2025-12-10 | Jerome Wong | Chief Financial Officer | Sell | — | — |
| 2025-12-10 | Jason C Jones | Chief Operating Officer | Sell | — | — |
| 2025-11-12 | Jason C Jones | Chief Operating Officer | Sell | — | — |
| 2025-11-12 | Scott G. Davis | CEO | Sell | — | — |
| 2025-11-12 | Jerome Wong | Chief Financial Officer | Sell | — | — |
| 2025-11-07 | Jason C Jones | Chief Operating Officer | A | — | — |
| 2025-11-07 | Scott G. Davis | CEO | A | — | — |
| 2025-11-07 | Jerome Wong | Chief Financial Officer | A | — | — |
| 2025-05-19 | Corinna Lathan | Director | A | — | — |
| 2025-05-19 | Deborah Lafer Scher | Director | A | — | — |
| 2025-05-19 | Mary Ann Cloyd | Director | A | — | — |
| 2025-05-19 | Kecheng Li | Director | A | — | — |
| 2025-03-18 | Scott G. Davis | CEO | A | — | — |
| 2025-03-18 | Jason C Jones | Chief Operating Officer | A | — | — |
| 2025-03-18 | Jerome Wong | Chief Financial Officer | A | — | — |
| 2024-06-26 | Kecheng Li | Director | A | — | — |
| 2024-06-26 | Mary Ann Cloyd | Director | A | — | — |
| 2024-06-26 | Corinna Lathan | Director | A | — | — |
| 2024-06-26 | Deborah Lafer Scher | Director | A | — | — |
| 2024-04-04 | Jerome Wong | Chief Financial Officer | A | — | — |
| 2024-04-04 | Jason C Jones | Chief Operating Officer | A | — | — |
| 2024-04-04 | Jason C Jones | Chief Operating Officer | A | — | — |
| 2024-03-14 | Corinna Lathan | Director | Buy | — | — |
| 2023-08-18 | Jerome Wong | Chief Financial Officer | Sell | — | — |
| 2023-08-18 | Scott G. Davis | President & COO | Sell | — | — |
| 2023-06-27 | Rhonda A. Wallen | Director | A | — | — |
| 2023-06-27 | Corinna Lathan | Director | A | — | — |
| 2023-06-27 | STEVEN SHERMAN | Executive Chair | A | — | — |
| 2023-06-27 | Kecheng Li | Director | A | — | — |
| 2023-06-27 | Mary Ann Cloyd | Director | A | — | — |
| 2023-06-16 | Corinna Lathan | Director | A | — | — |
| 2023-06-16 | Rhonda A. Wallen | Director | A | — | — |
| 2023-06-16 | Mary Ann Cloyd | Director | A | — | — |
| 2023-06-16 | Kecheng Li | Director | A | — | — |
| 2023-06-15 | STEVEN SHERMAN | Executive Chair | A | — | — |
| 2023-06-15 | Jason C Jones | Chief Operating Officer | A | — | — |
| 2023-06-15 | Jerome Wong | Chief Financial Officer | A | — | — |
| 2023-05-26 | STEVEN SHERMAN | Executive Chair | Sell | — | — |
| 2023-05-17 | Jason C Jones | Chief Operating Officer | Sell | — | — |
| 2023-05-17 | STEVEN SHERMAN | Executive Chair | M | — | — |
| 2022-12-07 | STEVEN SHERMAN | Executive Chair | MIXED | — | — |
| 2022-12-06 | Jason C Jones | Senior VP Product Development | A | — | — |
| 2022-12-06 | Stanley Stern | Director | A | — | — |
| 2022-11-23 | STEVEN SHERMAN | CEO & Chairman | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 435,432 | — |
| — | 10%+ Owner | 91,438 | — |
| — | CEO | 79,150 | — |
| — | 10%+ Owner | 52,291 | — |
| — | 10%+ Owner | 51,799 | — |
| — | Director | 30,827 | — |
| — | Director | 30,729 | — |
| — | Director | 30,447 | — |
| — | Chief Operating Officer | 30,070 | — |
| — | Executive Chair | 29,944 | — |
| — | Chief Financial Officer | 28,955 | — |
| — | Director | 20,961 | — |
| — | Director | 11,134 | — |
| — | President & CEO | 9,743 | — |
| — | Director | 9,486 | — |
| — | Director | 2,653 | — |
| — | Chief Financial Officer | 2,342 | — |
| — | See Remarks | 1,933 | — |
| — | President, EksoWorks | 1,767 | — |
| — | Director | 718 | — |
| — | Director | 647 | — |
| — | Chief Financial Officer | 360 | — |
| — | Vice Pres., Global Marketing | 115 | — |
| — | President & CEO | 90 | — |
| — | Chief Operating Officer | 79 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the EKSO quote page; the site-wide leaderboard is on the insider transactions hub.